Last reviewed · How we verify
NCT04789486
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Phase 1, PHASE2 trial testing AGuIX in Non-small Cell Lung Cancer in 100 participants. Currently enrolling.
10 April 2026
Quick facts
| Lead sponsor | Dana-Farber Cancer Institute |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 27 May 2021 |
| Primary completion | 10 April 2026 |
| Estimated completion | 10 September 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- AGuIX
- Radiotherapy — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Advanced Pancreatic Adenocarcinoma — all drugs for Advanced Pancreatic Adenocarcinoma →
- Unresectable Pancreatic Cancer — all drugs for Unresectable Pancreatic Cancer →
- Ductal Adenocarcinoma of the Pancreas — all drugs for Ductal Adenocarcinoma of the Pancreas →
Sponsor
Dana-Farber Cancer Institute
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer or Advanced Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246 -
Cancer nanotechnology: current status and perspectives.
Kemp JA, Kwon YJ. · · 2021 · cited 117× · PMID 34727233 · DOI 10.1186/s40580-021-00282-7 -
New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.
Gawne PJ, Ferreira M, Papaluca M, Grimm J, et al · · 2023 · cited 112× · PMID 39022623 · DOI 10.1038/s41578-023-00581-x -
Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.
Nirmala MJ, Kizhuveetil U, Johnson A, G B, et al · · 2023 · cited 86× · PMID 36926304 · DOI 10.1039/d2ra07863e -
Advances of medical nanorobots for future cancer treatments.
Kong X, Gao P, Wang J, Fang Y, et al · · 2023 · cited 74× · PMID 37452423 · DOI 10.1186/s13045-023-01463-z -
Nanomaterial-based contrast agents.
Hsu JC, Tang Z, Eremina OE, Sofias AM, et al · · 2023 · cited 69× · PMID 38130699 · DOI 10.1038/s43586-023-00211-4 -
Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment.
Yu S, Wang Y, He P, Shao B, et al · · 2022 · cited 59× · PMID 35198442 · DOI 10.3389/fonc.2022.809304 -
Prospects of nanoparticle-based radioenhancement for radiotherapy.
Gerken LRH, Gerdes ME, Pruschy M, Herrmann IK. · · 2023 · cited 53× · PMID 37555747 · DOI 10.1039/d3mh00265a
Verify or expand the search:
- PubMed search for NCT04789486
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AGuIX
Trials testing the same drug.
- NCT04094077 — Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases · Phase 2 · terminated
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
- NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
- NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04789486 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
- Last refreshed: 23 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04789486.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing